169 related articles for article (PubMed ID: 32579820)
1. Vasoactive Intestinal Peptide in Checkpoint Inhibitor-Induced Pneumonitis.
Frye BC; Meiss F; von Bubnoff D; Zissel G; Müller-Quernheim J
N Engl J Med; 2020 Jun; 382(26):2573-2574. PubMed ID: 32579820
[No Abstract] [Full Text] [Related]
2. Anti-PD-1-associated organizing pneumonia in a responding melanoma patient.
Fiset PO; Shapera S; Butler MO; Tsao MS
Ann Oncol; 2016 Aug; 27(8):1649-50. PubMed ID: 27091805
[No Abstract] [Full Text] [Related]
3. Treatment of mycophenolate-resistant immune-related organizing pneumonia with infliximab.
Ortega Sanchez G; Jahn K; Savic S; Zippelius A; Läubli H
J Immunother Cancer; 2018 Sep; 6(1):85. PubMed ID: 30176946
[TBL] [Abstract][Full Text] [Related]
4. Autoimmune Polyarthritis Induced by Cancer Immunotherapy With Checkpoint Inhibitor.
Quresh Q; Quinet R
J Clin Rheumatol; 2017 Jun; 23(4):235. PubMed ID: 28538282
[No Abstract] [Full Text] [Related]
5. Clinical and radiological features of immune checkpoint inhibitor-related pneumonitis in lung cancer and non-lung cancers.
Nobashi TW; Nishimoto Y; Kawata Y; Yutani H; Nakamura M; Tsuji Y; Yoshida A; Sugimoto A; Yamamoto T; Alam IS; Noma S
Br J Radiol; 2020 Nov; 93(1115):20200409. PubMed ID: 32783627
[TBL] [Abstract][Full Text] [Related]
6. Pneumonitis: a serious adverse effect of PD-L1 inhibitors including pembrolizumab.
Rickard F; Hyams C; Low AT
BMJ Case Rep; 2018 May; 2018():. PubMed ID: 29735504
[TBL] [Abstract][Full Text] [Related]
7. Antiprogrammed Cell Death-1 Immunotherapy-Related Secondary Sclerosing Cholangitis.
Ogawa K; Kamimura K; Terai S
Hepatology; 2019 Feb; 69(2):914-916. PubMed ID: 30033637
[No Abstract] [Full Text] [Related]
8. Thoracic Imaging of Non-Small Cell Lung Cancer Treated With Anti-programmed Death Receptor-1 Therapy.
Hammer M; Bagley S; Aggarwal C; Bauml J; Nachiappan AC; Simone CB; Langer C; Katz SI
Curr Probl Diagn Radiol; 2019; 48(2):142-147. PubMed ID: 29573843
[TBL] [Abstract][Full Text] [Related]
9. Radiologic and autopsy findings in a case of fatal immune checkpoint inhibitor-associated pneumonitis.
Shea M; Rangachari D; Hallowell RW; Hollie NI; Costa DB; VanderLaan PA
Cancer Treat Res Commun; 2018; 15():17-20. PubMed ID: 30207283
[TBL] [Abstract][Full Text] [Related]
10. [Pembrolizumab for the treatment of melanoma: updates and perspectives.].
Chiarion Sileni V; Mandalà M; Queirolo P
Recenti Prog Med; 2017 Dec; 108(12):528-531. PubMed ID: 29297903
[TBL] [Abstract][Full Text] [Related]
11. Risk of Pneumonitis and Pneumonia Associated With Immune Checkpoint Inhibitors for Solid Tumors: A Systematic Review and Meta-Analysis.
Su Q; Zhu EC; Wu JB; Li T; Hou YL; Wang DY; Gao ZH
Front Immunol; 2019; 10():108. PubMed ID: 30778352
[No Abstract] [Full Text] [Related]
12. Recurrent Pneumonitis in Patients with Melanoma Treated with Immune Checkpoint Inhibitors.
Asher N; Marom EM; Ben-Betzalel G; Baruch EN; Steinberg-Silman Y; Schachter J; Shapira-Frommer R; Markel G
Oncologist; 2019 May; 24(5):640-647. PubMed ID: 30777894
[TBL] [Abstract][Full Text] [Related]
13. Alemtuzumab for Immune-Related Myocarditis Due to PD-1 Therapy.
Esfahani K; Buhlaiga N; Thébault P; Lapointe R; Johnson NA; Miller WH
N Engl J Med; 2019 Jun; 380(24):2375-2376. PubMed ID: 31189042
[No Abstract] [Full Text] [Related]
14. A false alarm of COVID-19 pneumonia in lung cancer with anti-PD-1 related pneumonitis: a case report and review of the literature.
Dai Y; Liu S; Zhang Y; Li X; Zhao Z; Liu P; Du Y
J Med Case Rep; 2021 Feb; 15(1):41. PubMed ID: 33522942
[TBL] [Abstract][Full Text] [Related]
15. Atrophic exocrine pancreatic insufficiency associated with anti-PD1 therapy.
Hoadley A; Sandanayake N; Long GV
Ann Oncol; 2017 Feb; 28(2):434-435. PubMed ID: 27864215
[No Abstract] [Full Text] [Related]
16. [Grover's-like drug eruption under anti-PD-1 therapy for metastatic melanoma].
Amini-Adle M; Balme B; Dalle S
Ann Dermatol Venereol; 2018 Dec; 145(12):802-803. PubMed ID: 30415933
[No Abstract] [Full Text] [Related]
17. Immune Checkpoint Inhibitor Therapy-related Pneumonitis: Patterns and Management.
Kalisz KR; Ramaiya NH; Laukamp KR; Gupta A
Radiographics; 2019; 39(7):1923-1937. PubMed ID: 31584861
[TBL] [Abstract][Full Text] [Related]
18. Pembrolizumab-induced dermatomyositis in a patient with metastatic melanoma.
Berger M; Legeay AL; Souci S; Streichenberger N; Thomas L; Dalle S
Eur J Cancer; 2018 Nov; 104():227-230. PubMed ID: 30322679
[No Abstract] [Full Text] [Related]
19. High incidence and early onset of nivolumab-induced pneumonitis: four case reports and literature review.
Koyama N; Iwase O; Nakashima E; Kishida K; Kondo T; Watanabe Y; Takahashi H; Umebayashi Y; Ogawa Y; Miura H
BMC Pulm Med; 2018 Jan; 18(1):23. PubMed ID: 29378571
[TBL] [Abstract][Full Text] [Related]
20. Immunotherapy-induced sarcoidosis in patients with melanoma treated with PD-1 checkpoint inhibitors: Case series and immunophenotypic analysis.
Lomax AJ; McGuire HM; McNeil C; Choi CJ; Hersey P; Karikios D; Shannon K; van Hal S; Carr U; Crotty A; Gupta SK; Hollingsworth J; Kim H; Fazekas de St Groth B; McGill N
Int J Rheum Dis; 2017 Sep; 20(9):1277-1285. PubMed ID: 28480561
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
